Cresco Labs (OTCMKTS:CRLBF - Get Free Report) posted its earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01), Zacks reports. Cresco Labs had a negative net margin of 6.67% and a negative return on equity of 11.65%. The business had revenue of $163.62 million for the quarter, compared to analyst estimates of $162.00 million.
Cresco Labs Stock Performance
Shares of OTCMKTS:CRLBF traded up $0.07 during trading on Friday, reaching $0.75. 1,274,434 shares of the company's stock traded hands, compared to its average volume of 942,176. Cresco Labs has a 12 month low of $0.43 and a 12 month high of $2.05. The company has a debt-to-equity ratio of 1.63, a current ratio of 2.75 and a quick ratio of 1.98. The stock has a market capitalization of $366.59 million, a P/E ratio of -5.74 and a beta of 1.42. The company has a 50 day moving average of $0.57 and a 200-day moving average of $0.70.
Analyst Ratings Changes
Separately, Canaccord Genuity Group lowered shares of Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a report on Tuesday, June 3rd. Two investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy".
View Our Latest Stock Report on CRLBF
About Cresco Labs
(
Get Free Report)
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Read More

Before you consider Cresco Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cresco Labs wasn't on the list.
While Cresco Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.